ivWatch in Prevention of Extravasation of Vesicants in an Oncology Setting

Launched by ROSWELL PARK CANCER INSTITUTE · Dec 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the use of a device called ivWatch to help detect if an intravenous (IV) line is leaking fluid into the surrounding tissue. When you receive certain medications, especially for cancer treatment, it’s important that the IV fluid stays in the vein. If it leaks out, it can cause harm to the nearby tissue. The ivWatch device aims to identify these leaks early, before any visible signs appear, which could help prevent damage.

To participate in this study, patients need to be receiving specific types of medications—known as vesicants—that can be harmful if they leak. Eligible participants must have a peripheral IV already in place and should be able to understand the study details and give consent. However, those with certain skin conditions near the IV site or who are not receiving these specific medications won’t qualify. If you join the trial, you can expect to use the ivWatch device during your treatment to help ensure your safety. This study is currently looking for participants, so if you think you might be eligible, it could be worth discussing with your healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients requiring a peripheral IV for infusion of vesicant or vesicant-like agents (chemotherapy, other vesicant medications).
• • PIV must be inserted
• • Participant (or legal representative) must understand the nature of this study and verbally consent with the Research Study Information Sheet prior to receiving any study related procedure
• Exclusion Criteria:
• • Patients who are not getting a vesicant, irritant or vesicant like fluid infused.
• • Patients who are bruised, scarred, or tattooed in the area of the PIV.
• • Patients with skin integrity issues at the site of the PIV.
• • Patients who are on "light precautions."
• • Not for use in power injectors.
• • Not for use on mediports, implanted ports, IVAD, central lines, PICC lines.
• • Patients without a cancer diagnosis.